CTOs on the Move

20/20 GeneSystems Inc

www.2020gene.com

 
20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.2020gene.com
  • 9430 Key West Ave
    Rockville, MD USA 20850
  • Phone: 240.453.6339

Executives

Name Title Contact Details

Similar Companies

Mindstrong Health

Mindstrong was founded by some of the world`s leading authorities in neuroscience, oncology, and technology. It is based on their shared vision to redefine neuropsychiatric healthcare, transforming diagnosis and delivering precision therapy. Mindstrong builds on one of the founder`s patented biomarker platform developed over years of extensive clinical R&D.

Oxyband Technologies

Oxyband Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADF Engineering Inc

ADF Engineering Inc is a Miamisburg, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

genscript

genscript is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets.